Group B strep antigen tests inadequate for maternity/infant diagnosis -- FDA safety alert.
This article was originally published in The Gray Sheet
GROUP B STREP ANTIGEN TEST COMPARISON TO BROTH CULTURE TEST IN CLINICAL TRIALS will be discussed at an upcoming meeting between FDA and manufacturers. The agency says that the meeting will address clinical parameters of comparison trials between the antigen tests and broth culture, the gold standard for detection of Group B streptococcal infection. Due to public health concerns about the sensitivity of the antigen tests, the agency is conditioning continued market availability of the tests on the comparison trial.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.